MicroRNA expression profiles in serous ovarian carcinoma

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2690-2695

  Nam, Eun Ji ^a   Yoon, Heejei ^b   Kim, Sang Wun ^a   Kim, Hoguen ^b   Kim, Young Tae ^a   Kim, Jae Hoon ^a   Kim, Jae Wook ^c   Kim, Sunghoon ^a,d  

^a Department of Obstetrics and Gynecology

^b Yonsei University   (South Korea)

^c Kwandong University College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; NORTHERN BLOTTING; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; UTERUS DISEASE; CYSTADENOCARCINOMA; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; OVARY; OVARY TUMOR;

CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIERS ESTIMATE; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; OVARY; PROGNOSIS;

EID: 50849137458     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1731     Document Type: Article

References (39)

1. Seidman JD, Kurman RJ. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 2003;17: 909-25, vii.
2. Shih le M, Kurman RJ Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004:164:1511 -8.
3. Chan WY Cheung KK, Schorge JO, et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000:156:409-17.
4. Ross JS, Yang F, Kallakury BV, Sheehan CE, Ambros RA, Muraca PJ. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol 1999;111: 311 -6.
5. Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992;89:9267-71.
6. Russell SE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004;203: 617-9.
7. Harmon GJ. RNA interference. Nature 2002;418: 244-51.
8. Lagos-Quintana M, Rauhut R, Lendeckel W.Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853-8.
9. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003;113: 673-6.
10. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-9.
11. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102:13944-9.
12. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6.
13. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120:635-47.
14. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. High expression of precursor micro-RNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 2004;39:167-9.
15. lorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.
16. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
17. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006;103:7024-9.
18. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006; 124:1169-81.
19. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793-801.
20. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006;24:4677-84.
21. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435: 834-8.
22. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
23. 23.Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98: 5116-21.
24. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res 2004;32:D109-11.
25. lorio MV.Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67: 8699-707.
26. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65:6029-33.
27. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:2113-29.
28. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY miR21-mediated tumor growth. Oncogene 2007;26: 2799-803.
29. Rosser CJ.Tanaka M, Pisters LL, et al. Adenoviral mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer GeneTher 2004;11:273-9.
30. Lee YS, Kim HK, Chung S, Kim KS, Dutta A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem 2005;280: 16635-41.
31. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of microRNA miR-125a or miR-125b. J Biol Chem 2007;282:1479-86.
32. Lassus H, Leminen A.Vayrynen A, et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004:92:31 -9.
33. Martin ES, Cesari R, Pentimalli F, et al.The BCSC-1 locus at chromosome 11q23-24 is a candidate tumor suppressor gene. Proc Natl Acad Sci U S A 2003:100: 11517-22.
34. BabakT, Zhang W, Morris Q, Blencowe BJ, Hughes TR. Probing microRNAs with microarrays: tissue specificity and functional inference. RNA 2004;10: 1813-9.
35. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overex-pressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32.
36. LinYW, Sheu JC, Liu LY, et al. Loss of heterozygosity at chromosome 13q in hepatocellular carcinoma: identification of three independent regions. Eur J Cancer 1999;35:1730-4.
37. Das S, Ongusaha PP.Yang YS, Park JM, Aaronson SA, Lee SW. Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-KB pathway activation. Cancer Res 2006;66:8123-30.
38. Kim SW, Kim JW, Kim YT, et al. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: potential predictive markers of chemoresistant-disease. Genes Chromosomes Cancer 2007;46:1 -9.
39. Zhang L, Huang J.Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006;103:9136-41.